Saudi Arabia is rapidly solidifying its position as the preeminent growth market for clinical trials within the Middle East, a…
Read More
Novartis Navigates Generics Storm in Q1, Eyes Robust Future Fueled by Strategic Acquisitions and Pipeline Advancements
Novartis reported a challenging first quarter for 2026, with profits experiencing a significant downturn primarily due to the intensified impact…
Read More
The Surge in Oncology Innovation Fuels Strategic Investment in HPAPI and ADC Manufacturing Capabilities
The accelerating demand for highly potent active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates (ADCs) is compelling contract development and manufacturing…
Read More
Eli Lilly Acquires Ajax Therapeutics for Up to $2.3 Billion in Strategic Move to Bolster Oncology Pipeline
Eli Lilly and Company has significantly expanded its oncology portfolio with the definitive agreement to acquire Ajax Therapeutics, a clinical-stage…
Read More
Labcorp and Children’s Hospital of Philadelphia Forge Strategic Alliance to Advance Pediatric Diagnostics and National Access
Labcorp, a leading global life sciences company, and the Children’s Hospital of Philadelphia (CHOP), a preeminent pediatric research and clinical…
Read More
OZMOSI and Planview Forge Strategic Alliance to Revolutionize Pharmaceutical R&D Planning with AI-Powered Clinical Intelligence
OZMOSI and Planview have announced a significant partnership aimed at transforming how pharmaceutical organizations approach research and development (R&D) planning.…
Read More
Nucleai and Sirona Dx Forge Strategic Alliance to Revolutionize Spatial Proteomics for Drug Development
The pharmaceutical and biotechnology sectors are poised for a significant leap forward in drug development with the formation of a…
Read More
Regeneron Pharmaceuticals and Telix Pharmaceuticals Forge Strategic Alliance to Advance Precision Oncology Through Radiopharmaceutical Innovation
Regeneron Pharmaceuticals and Telix Pharmaceuticals have announced a significant partnership aimed at accelerating the development and commercialization of novel radiopharmaceutical…
Read More
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers – Pharmaceutical Technology
The landscape of oncology drug development is undergoing a profound transformation, increasingly centered on precision immunotherapies where biomarker-defined patient populations…
Read More
Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies
Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies Roche, a global pharmaceutical giant,…
Read MoreYOU MAY HAVE MISSED
